TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of confirmed allergic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Microparticle/Nanoparticle number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microparticle/Nanoparticle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microparticle/Nanoparticle identity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Nicotine Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of BIOSECURE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in epinephrine serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in norepinephrine serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in cortisol serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in hs-CRP serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Myoglobin serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Steady-state Concentration (Css, av) of Oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Oral Clearance (CL/F) of Oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With All-causality and Treatment-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Durable response rate to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number/severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: global inhomogeneity (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Turesky modification of the Quigley and Hein Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to achieve transseptal access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: TSP Crosser Introducer steerability and positioning for ablation catheter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: TSP Crosser System usability
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Composite of PK parameters of dabrafenib and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulation ratio of dabrafenib and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective half-life of trametinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the ADAS-cog/11 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in the ADCS-CGIC score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of time of glucose levels spent between 3.9 and 10 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total number of patients who will be Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of SPD Feature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects achieving ACR20-CRP response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in DAS28-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Microvascular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: β-CIT SPECT imaging of the dopamine transporter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in tumour uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to wound healing (re-epithelialization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Elimination Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance of skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: clinical improvement in lymphadenopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic improvement in lymphadenopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood-Retinal Barrier function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance to dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immune response to H1N1 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of H1N1 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Pain assessment using the Face, Legs, Activity, Cry, Consolability scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment using the Visual Analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers associated with hepatoblastoma subtypes and cancer stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weekly minutes spent in aerobic and strengthening activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness in discouraging smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of tumor volume in the stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fear of Cancer Recurrence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose of SRA737
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended Phase 2 dose of SRA737
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ability to perform clinically relevant tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone Clearance Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With an Increase in BIS Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of Tacrolimus Blood Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of Quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline of Reduction in analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUCτ,ss of DA-1229 and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax,ss of DA-1229 and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor response to SBRT as assessed by FDG-PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of grade 3 or greater non-hematologic acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Visual Analogue Scale (VAS) pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Glycosylated Hemoglobin at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Body Mass Index at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Length-for-age z Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Lactulose From Dual Sugar Absorption Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of days to first adult diabetes care visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to the diabetes care regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Warfarin adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Height Z-score at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with acute exacerbations of chronic obstructive pulmonary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain degree
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Observed Serum Concentration (Cmax) for AAB-003 at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Boston bowel preparation scale (BBPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With LV Lead-related Serious Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: No microscopic evidence of viable tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with chronic pain or pain syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant tumor control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Long-term side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of dizziness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthmatic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of major and minor adverse events due to thromboembolic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of major and minor bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient contentment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Inventory of Mood and Anxiety Symptoms (IMAS-R) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mechanism of labor assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: 6-month Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Breastfeeding outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wechsler Preschool & Primary Scale of Intelligence™ (WPPSI™-IV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of scleral inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain medication dosage and frequency of use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in opioid misuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in chronic pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tuckman Condensed Procrastination Scale (TCPS) Change (Video One)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Tuckman Condensed Procrastination Scale (TCPS) Change (Video Two)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score of vividness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in cognition symptoms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Timely imaging evaluation within 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Wisconsin Card Sorting Test (WCST) performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Probabilistic Reversal Learning (PRL) performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Flanker Task performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Equivalence of glare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectrum of NAFLD in HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Elasticity measured with the Fibroscan XL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of NVAF patients receiving 20 mg Rivaroxaban
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of NVAF patients receiving 15 mg Rivaroxaban
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Exclusive breastfeeding duration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quantity of fibrosis on tissue muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of seroconversion for SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pathologic Response Rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: House-Brackmann scale (Global Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Severity of Abdominal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Need for Opioids Between Device and Sham
Endpoint domain: Adverse events/effects
Primary endpoint: Anxiety Sensitivity Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gluten degradation in the duodenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of PICD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Global Impression--Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pediatric Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage change in tumor Ktrans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scleral thinning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of occurrence of Radiodermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Molecular relapse (MR) free survival
Endpoint domain: Mortality/survival
Primary endpoint: Absolute Treg number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treg function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Number of Additional Avastin Injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from Baseline in Vulvovaginal Symptom Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline: PTSD Checklist-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline: West Haven-Yale Multidimensional Pain Inventory- Interference Subscale (WHY-MPI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline: Pain Catastrophizing Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Children Screened for Developmental Delay
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Responder Rate Based on MIHAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody formation against agalsidase alfa and beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum change in vaginal pulse amplitude (VPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High Density Lipoprotein Cholesterol (HDL-c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment efficacy in acral vitiligo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of teicoplanin in treating S.aureus bone and joint infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of visual acuity in ETDRS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort (Subjective Rating Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comfort Preference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Benefit Response Rate (CBRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of penile implant insertions and re-insertions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Bleeding Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demanded numbers of bolus button
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of ≥ 3 New T2 Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Time between symptomatic malignant ascites episodes requiring paracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Lopinavir/Ritonavir Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Brain Penetrance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hypometabolic patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of drug craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type and severity of stimulant withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical physiological response to cocaine challenge - especially adverse effects measures
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of ultrasound scans with DSC >0.90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of variation between expert-drawn contours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour mean diastolic blood pressure (DBP) after a missed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mean DBP during the last 6 hours of the 24-hour dosing interval after an active dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low Anterior Resection Syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Infants Serum Triglyceride Level Higher Than 200 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from 0 to any time before the last quantifiable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from 0 to infinite time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of obstructive sleep apnoea (OSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic performance for detecting bone metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Grade > 3 Treatment-related Pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Local Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of 70%+ in the Urogenital Distress Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Very Much or Much Better on the Patient Global Impression of Improvement Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of each and of all headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of VRC-HIVMAB080-00-AB
Endpoint domain: Adverse events/effects
Primary endpoint: Normal lumbal CSF index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes